Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;38(2):589-596.
doi: 10.1007/s40620-024-02171-8. Epub 2024 Dec 15.

Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies

Salvatore De Cosmo  1 , Roberto Pontremoli  2 , Annalisa Giandalia  3 , Valeria Manicardi  4 , Alberto Rocca  5 , Antonio Nicolucci  6 , Maria Chiara Rossi  6 , Giuseppe Lucisano  6 , Giusi Graziano  6 , Paolo Di Bartolo  7 , Graziano Di Cianni  8 , Riccardo Candido  9 , Giuseppina T Russo  10 ; AMD Annals Study Group
Affiliations

Generalizability of kidney and cardiovascular protection by finerenone to the real world in Italy: insights from Fidelio and Figaro studies

Salvatore De Cosmo et al. J Nephrol. 2025 Mar.

Abstract

Background: We evaluated the proportion of Type 2 diabetes (T2D) patients with chronic kidney disease (CKD) participating in the AMD (Association of Medical Diabetologists) Annals initiative who met the eligibility criteria for phase III-studies on finerenone, showing its renal and cardiovascular benefits.

Methods: This analysis involved all T2D patients seen in 2019 in 282 diabetes centers in Italy, for whom data on kidney function (estimated glomerular filtration rate and albuminuria) were available. Data are presented separately for different scenarios, covering the population with main eligibility criteria for inclusion in the FIDELIO-DKD and FIGARO-DKD trials.

Results: Among 343,037 T2D patients involved in the analysis, 5.4% met the eligibility criteria of the FIDELIO-DKD study (13.3% if we consider the population with fundus data) and 22.3% met those of the FIGARO-DKD trial. Overall, 110,000 (33%) patients were eligible for treatment with finerenone, with a male prevalence, an average age of 71 years, and good control of the main risk factors (HbA1c 7.3%; BP 138/76 mmHg; LDL-c 87 mg/dl), albeit with large percentages of not well controlled patients (50% with SBP > 140 mmHg; > 30% with LDL-c > 100 mg/dl). Over 12% were on sodium/glucose cotransporter 2 inhibitors or glucagon-like peptide 1 receptor agonists. Based on the event rate from the FIDELITY pooled analysis, the number of potentially avoidable events was 21.7 per 1000 eligible patients for the cardiovascular composite outcome and 16.7 for the renal outcome.

Conclusions: This analysis showed that approximately 33% of patients with T2D present the main eligibility criteria for treatment with finerenone and could therefore benefit from it in the near future.

Keywords: AMD Annals; CKD; Finerenone; T2D.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors have no competing interests to disclose. Ethical approval: Local ethics committees of each participating center approved the study protocol. Human and animal rights statement: All Authors declare: this research did not involve animals. The research was conducted on human subjects, following procedures in accordance with the ethical standards of the responsible Committees (this is a retrospective multicenter study) on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008. Informed consent: Given the anonymous nature of the study, based on the Italian regulations, informed consent is not requested.

References

    1. Xie Y, Bowe B, Mokdad AH, Xian H, Yan Y, Li T, Maddukuri G, Tsai CY, Floyd T, Al-Aly Z (2018) Analysis of the Global Burden of Disease study highlights the global, regional, and national trends of chronic kidney disease epidemiology from 1990 to 2016. Kidney Int 94:567–581 - PubMed
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5S):S1–S127
    1. Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V (2021) Chronic kidney disease. Lancet 398:786–802 - PubMed
    1. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A et al (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. Kidney Int 79:1341–1352 - PubMed
    1. TuFle KR, Bakris GL, Bilous RW et al (2014) Diabetic kidney disease: a report from an ADA consensus conference. Diabetes Care 37:2864–2883

MeSH terms

LinkOut - more resources